Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Trial protocol for the validation of the 'Toronto Aortic Stenosis Quality of Life (TASQ) Questionnaire' in patients undergoing surgical aortic valve replacement (SAVR) or transfemoral (TF) transcatheter aortic valve implantation (TAVI): the TASQ registry

D. Frank, S. Kennon, N. Bonaros, M. Romano, T. Lefèvre, C. Di Mario, P. Stefàno, FL. Ribichini, D. Himbert, M. Urena-Alcazar, J. Salgado-Fernandez, JJ. Cuenca Castillo, B. Garcia, J. Kurucova, M. Thoenes, C. Lüske, P. Bramlage, R. Styra,

. 2019 ; 6 (1) : e001008. [pub] 20190521

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028861

Background: Patients with severe aortic stenosis (AS) have a reduced life expectancy and quality of life (QoL), owing to advanced age and the presence of multiple comorbidities. Currently, there is no AS-specific QoL measurement tool, which prevents an accurate assessment of how this chronic condition and its treatment affect patients. The Toronto Aortic Stenosis Quality of Life Questionnaire (TASQ) was developed in order to address this deficiency. Methods: The present trial protocol was designed to enable validation of the TASQ, which has been produced in five languages (English, French, German, Italian and Spanish) to increase usability. Patients with severe AS who are undergoing surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI) will be asked to complete the TASQ and, for comparative purposes, the Kansas City Cardiomyopathy Questionnaire and the general health-related QoL Short Form-12 questionnaire. The questionnaires will be completed prior to the intervention, at discharge, as well as at 30 days and 3 months follow-up. A total of 290 patients will be recruited across one Canadian and nine European centres. Overall, the protocol validation aims to include 120 patients undergoing transfemoral TAVI (TF-TAVI), 120 undergoing SAVR and up to 50 being treated medically. The primary objective of the registry is to validate the TASQ in five different languages. The secondary objective is to assess the utility of the TASQ for assessing differences in QoL outcome between patients undergoing TF-TAVI, SAVR or medical management for their AS. Discussion: Validation and roll-out of the TASQ will enable clinicians to capture an accurate assessment of how AS and its management affects the QoL of patients and will help them to determine the most appropriate treatment strategy for individual patients. Trial registration number: NCT03186339.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028861
003      
CZ-PrNML
005      
20190823133101.0
007      
ta
008      
190813s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/openhrt-2019-001008 $2 doi
035    __
$a (PubMed)31218003
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Frank, Derk $u Departmentof Internal Medicine III (Cardiology, Angiology and Intensive Care Medicine), UKSH University Clinical Center Schleswig-Holstein, Kiel, Germany and DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany.
245    10
$a Trial protocol for the validation of the 'Toronto Aortic Stenosis Quality of Life (TASQ) Questionnaire' in patients undergoing surgical aortic valve replacement (SAVR) or transfemoral (TF) transcatheter aortic valve implantation (TAVI): the TASQ registry / $c D. Frank, S. Kennon, N. Bonaros, M. Romano, T. Lefèvre, C. Di Mario, P. Stefàno, FL. Ribichini, D. Himbert, M. Urena-Alcazar, J. Salgado-Fernandez, JJ. Cuenca Castillo, B. Garcia, J. Kurucova, M. Thoenes, C. Lüske, P. Bramlage, R. Styra,
520    9_
$a Background: Patients with severe aortic stenosis (AS) have a reduced life expectancy and quality of life (QoL), owing to advanced age and the presence of multiple comorbidities. Currently, there is no AS-specific QoL measurement tool, which prevents an accurate assessment of how this chronic condition and its treatment affect patients. The Toronto Aortic Stenosis Quality of Life Questionnaire (TASQ) was developed in order to address this deficiency. Methods: The present trial protocol was designed to enable validation of the TASQ, which has been produced in five languages (English, French, German, Italian and Spanish) to increase usability. Patients with severe AS who are undergoing surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI) will be asked to complete the TASQ and, for comparative purposes, the Kansas City Cardiomyopathy Questionnaire and the general health-related QoL Short Form-12 questionnaire. The questionnaires will be completed prior to the intervention, at discharge, as well as at 30 days and 3 months follow-up. A total of 290 patients will be recruited across one Canadian and nine European centres. Overall, the protocol validation aims to include 120 patients undergoing transfemoral TAVI (TF-TAVI), 120 undergoing SAVR and up to 50 being treated medically. The primary objective of the registry is to validate the TASQ in five different languages. The secondary objective is to assess the utility of the TASQ for assessing differences in QoL outcome between patients undergoing TF-TAVI, SAVR or medical management for their AS. Discussion: Validation and roll-out of the TASQ will enable clinicians to capture an accurate assessment of how AS and its management affects the QoL of patients and will help them to determine the most appropriate treatment strategy for individual patients. Trial registration number: NCT03186339.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kennon, Simon $u Department of Cardiology, Barts Heart Centre, St. Bartholomew's Hospital London, London, UK.
700    1_
$a Bonaros, Nikolaos $u Departmentof Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria.
700    1_
$a Romano, Mauro $u Departmentof Thoracic and Cardiovascular Surgery, Department of Interventional Cardiology, Hopital Privé Jacques Cartier, Massy, France.
700    1_
$a Lefèvre, Thierry $u Departmentof Thoracic and Cardiovascular Surgery, Department of Interventional Cardiology, Hopital Privé Jacques Cartier, Massy, France.
700    1_
$a Di Mario, Carlo $u Department of Structural Interventional Cardiology, Department of Cardiac Surgery, Careggi University Hospital, Florence, Italy.
700    1_
$a Stefàno, Pierluigi $u Department of Structural Interventional Cardiology, Department of Cardiac Surgery, Careggi University Hospital, Florence, Italy.
700    1_
$a Ribichini, Flavio Luciano $u Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.
700    1_
$a Himbert, Dominique $u Department of Cardiology, Bichat-Claude Bernard Hospital, Paris, France.
700    1_
$a Urena-Alcazar, Marina $u Department of Cardiology, Bichat-Claude Bernard Hospital, Paris, France.
700    1_
$a Salgado-Fernandez, Jorge $u Department of Cardiology, Department of Cardiovascular Surgery, Hospital Juan Canalejo, Coruña, Spain.
700    1_
$a Cuenca Castillo, Jose Joaquin $u Department of Cardiology, Department of Cardiovascular Surgery, Hospital Juan Canalejo, Coruña, Spain.
700    1_
$a Garcia, Bruno $u Department of Cardiology, Hospital Vall d'Hebron, Barcelona, Spain.
700    1_
$a Kurucova, Jana $u Edwards Lifesciences, Prague, Czech Republic.
700    1_
$a Thoenes, Martin $u Edwards Lifesciences, Nyon, Switzerland.
700    1_
$a Lüske, Claudia $u Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.
700    1_
$a Bramlage, Peter $u Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.
700    1_
$a Styra, Rima $u Department of Psychiatry, University Health Network, Toronto, Ontario, Canada.
773    0_
$w MED00186378 $t Open heart $x 2053-3624 $g Roč. 6, č. 1 (2019), s. e001008
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31218003 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190823133316 $b ABA008
999    __
$a ind $b bmc $g 1434010 $s 1067321
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 6 $c 1 $d e001008 $e 20190521 $i 2053-3624 $m Open heart $n Open Heart $x MED00186378
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace